Suppressive chemoprophylaxis invites avoidable risk of serious illness caused by Plasmodium vivax malaria.
Despite inadequacy in preventing vivax malaria after travel, suppressive chemoprophylaxis has dominated travel medicine strategy since the advent of chloroquine in 1946. The lethal threat of falciparum malaria versus the perceived benign consequence of vivax malaria underpins this strategic posture....
| 第一著者: | |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
2013
|